10-Q Filing

Dominari Holdings Inc. CIK: 12239 Q2 2021

Filing Information

Form Type	10-Q
Accession Number	`0001213900-21-041640`
Period End Date	20210630
Filing Date	20210811
Fiscal Year	2021
Fiscal Period	Q2
XBRL Instance	f10q0621_aikidopharma_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 56 Income Statement 52 Cash Flow Statement 62 Stockholders Equity 26

Balance Sheet 56 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in Dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in Dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, authorized	`PreferredStockSharesAuthorized`	50.00M	shares	Point-in-time
Preferred stock, authorized	`PreferredStockSharesAuthorized`	50.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.71M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.72M	USD	Point-in-time
Marketable securities	`MarketableSecurityCurrent`	$24.80M	USD	Point-in-time
Marketable securities	`MarketableSecurityCurrent`	$87.83M	USD	Point-in-time
Prepaid expenses and other assets	`PrepaidExpenseAndOtherAssetsCurrent`	$176.00K	USD	Point-in-time
Prepaid expenses and other assets	`PrepaidExpenseAndOtherAssetsCurrent`	$215.00K	USD	Point-in-time
Common stock, authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Short-term investment	`ShortTermInvestments`	-	USD	Point-in-time
Short-term investment	`ShortTermInvestments`	$1.87M	USD	Point-in-time
Common stock, authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Deposits	`DepositsAssetsCurrent`	-	USD	Point-in-time
Deposits	`DepositsAssetsCurrent`	$4.48M	USD	Point-in-time
Common stock, issued	`CommonStockSharesIssued`	89.53M	shares	Point-in-time
Common stock, issued	`CommonStockSharesIssued`	34.92M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$102.07M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	89.53M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$27.73M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	34.92M	shares	Point-in-time
Convertible note receivable	`NotesReceivableRelatedPartiesNoncurrent`	$2.07M	USD	Point-in-time
Convertible note receivable	`NotesReceivableRelatedPartiesNoncurrent`	-	USD	Point-in-time
Investments	`Investments`	-	USD	Point-in-time
Investments	`Investments`	$2.76M	USD	Point-in-time
Total assets	`Assets`	$30.50M	USD	Point-in-time
Total assets	`Assets`	$104.14M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$319.00K	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$567.00K	USD	Point-in-time
Accrued salaries and benefits	`EmployeeRelatedLiabilitiesCurrent`	$733.00K	USD	Point-in-time
Accrued salaries and benefits	`EmployeeRelatedLiabilitiesCurrent`	$310.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.05M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$877.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$877.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$1.05M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.0001 par value, 100,000,000 shares authorized; 89,531,149 and 34,920,222 shares issued at June 30, 2021 and December 31, 2020, respectively; 89,531,146 and 34,920,219 shares outstanding at June 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$3.00K	USD	Point-in-time
Common stock, $0.0001 par value, 100,000,000 shares authorized; 89,531,149 and 34,920,222 shares issued at June 30, 2021 and December 31, 2020, respectively; 89,531,146 and 34,920,219 shares outstanding at June 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$9.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$265.25M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$186.48M	USD	Point-in-time
Treasury stock, at cost, 3 shares at June 30, 2021 and December 31, 2020	`TreasuryStockValue`	$264.00K	USD	Point-in-time
Treasury stock, at cost, 3 shares at June 30, 2021 and December 31, 2020	`TreasuryStockValue`	$264.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-156.60M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-161.92M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$29.62M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$31.49M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$10.53M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$104.37M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$103.08M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$20.98M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$30.50M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$104.14M	USD	Point-in-time

Income Statement 52 line items

Line Item	Tag	Value	Unit	Period
General and administrative	`SellingGeneralAndAdministrativeExpense`	$2.32M	USD	2 Qtrs
General and administrative	`SellingGeneralAndAdministrativeExpense`	$3.56M	USD	2 Qtrs
General and administrative	`SellingGeneralAndAdministrativeExpense`	$2.34M	USD	1 Quarter
General and administrative	`SellingGeneralAndAdministrativeExpense`	$1.02M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$675.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$397.00K	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$760.00K	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$325.00K	USD	1 Quarter
Research and development - license acquired	`ResearchAndDevelopmentLicenseAcquired`	$91.00K	USD	1 Quarter
Research and development - license acquired	`ResearchAndDevelopmentLicenseAcquired`	$1.11M	USD	2 Qtrs
Research and development - license acquired	`ResearchAndDevelopmentLicenseAcquired`	$1.12M	USD	2 Qtrs
Research and development - license acquired	`ResearchAndDevelopmentLicenseAcquired`	$102.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$2.76M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.79M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$5.08M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$4.19M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-1.79M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-5.08M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-2.76M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-4.19M	USD	2 Qtrs
Other income	`OtherIncome`	-	USD	1 Quarter
Other income	`OtherIncome`	$15.00K	USD	2 Qtrs
Other income	`OtherIncome`	$135.00K	USD	2 Qtrs
Other income	`OtherIncome`	$15.00K	USD	1 Quarter
Interest income	`InterestIncomeExpenseNet`	$40.00K	USD	1 Quarter
Interest income	`InterestIncomeExpenseNet`	-	USD	2 Qtrs
Interest income	`InterestIncomeExpenseNet`	-	USD	1 Quarter
Interest income	`InterestIncomeExpenseNet`	$67.00K	USD	2 Qtrs
Gains on marketable securities	`MarketableSecuritiesGainLoss`	$1.12M	USD	1 Quarter
Gains on marketable securities	`MarketableSecuritiesGainLoss`	$262.00K	USD	2 Qtrs
Gains on marketable securities	`MarketableSecuritiesGainLoss`	$459.00K	USD	2 Qtrs
Gains on marketable securities	`MarketableSecuritiesGainLoss`	$1.80M	USD	1 Quarter
Change in fair value of investment	`GainLossOnInvestments`	$-6.73M	USD	2 Qtrs
Change in fair value of investment	`GainLossOnInvestments`	$-431.00K	USD	1 Quarter
Change in fair value of investment	`GainLossOnInvestments`	$-1.66M	USD	1 Quarter
Change in fair value of investment	`GainLossOnInvestments`	$-898.00K	USD	2 Qtrs
Total other income (expenses)	`OtherNonoperatingIncomeExpense`	$-6.45M	USD	2 Qtrs
Total other income (expenses)	`OtherNonoperatingIncomeExpense`	$-519.00K	USD	1 Quarter
Total other income (expenses)	`OtherNonoperatingIncomeExpense`	$-237.00K	USD	2 Qtrs
Total other income (expenses)	`OtherNonoperatingIncomeExpense`	$1.41M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.31M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.65M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-5.31M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-1.35M	USD	1 Quarter
Basic and Diluted (in Dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Basic and Diluted (in Dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.07	USD	2 Qtrs
Basic and Diluted (in Dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.07	USD	1 Quarter
Basic and Diluted (in Dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.50	USD	2 Qtrs
Basic and Diluted (in Shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	21.09M	shares	2 Qtrs
Basic and Diluted (in Shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89.60M	shares	1 Quarter
Basic and Diluted (in Shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	32.98M	shares	1 Quarter
Basic and Diluted (in Shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	75.02M	shares	2 Qtrs

Cash Flow Statement 62 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-2.31M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.65M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-5.31M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-1.35M	USD	1 Quarter
Change in fair value of investment	`ChangeInFairValueOfInvestments`	$898.00K	USD	2 Qtrs
Change in fair value of investment	`ChangeInFairValueOfInvestments`	$6.73M	USD	2 Qtrs
Research and development-acquired license, expensed	`ResearchAndDevelopmentacquiredLicenseExpensed`	$1.11M	USD	2 Qtrs
Research and development-acquired license, expensed	`ResearchAndDevelopmentacquiredLicenseExpensed`	$1.12M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$175.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	-	USD	2 Qtrs
Realized gain on marketable securities	`MarketableSecuritiesRealizedGainLoss`	$597.00K	USD	1 Quarter
Realized gain on marketable securities	`MarketableSecuritiesRealizedGainLoss`	$544.00K	USD	2 Qtrs
Realized gain on marketable securities	`MarketableSecuritiesRealizedGainLoss`	$661.00K	USD	1 Quarter
Realized gain on marketable securities	`MarketableSecuritiesRealizedGainLoss`	$1.08M	USD	2 Qtrs
Unrealized loss on marketable securities	`MarketableSecuritiesUnrealizedGainLoss`	$-1.40M	USD	2 Qtrs
Unrealized loss on marketable securities	`MarketableSecuritiesUnrealizedGainLoss`	$653.00K	USD	1 Quarter
Unrealized loss on marketable securities	`MarketableSecuritiesUnrealizedGainLoss`	$-614.00K	USD	2 Qtrs
Unrealized loss on marketable securities	`MarketableSecuritiesUnrealizedGainLoss`	$212.00K	USD	1 Quarter
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-39.00K	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-76.00K	USD	2 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-248.00K	USD	2 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$608.00K	USD	2 Qtrs
Accrued salaries and benefits	`IncreaseDecreaseInAccruedSalaries`	$-389.00K	USD	2 Qtrs
Accrued salaries and benefits	`IncreaseDecreaseInAccruedSalaries`	$423.00K	USD	2 Qtrs
Interest receivable on convertible note	`IncreaseDecreaseInNotesReceivables`	$67.00K	USD	2 Qtrs
Interest receivable on convertible note	`IncreaseDecreaseInNotesReceivables`	-	USD	2 Qtrs
Payable to DatChat	`IncreaseDecreaseInPayablesToDatchat`	-	USD	2 Qtrs
Payable to DatChat	`IncreaseDecreaseInPayablesToDatchat`	$50.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.66M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.39M	USD	2 Qtrs
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$86.50M	USD	2 Qtrs
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$78.04M	USD	2 Qtrs
Sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$52.22M	USD	2 Qtrs
Sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$23.16M	USD	2 Qtrs
Sale of Hoth common shares	`ProceedsFromSaleOfCommonStock`	-	USD	2 Qtrs
Sale of Hoth common shares	`ProceedsFromSaleOfCommonStock`	$460.00K	USD	2 Qtrs
Funds to deposit accounts, net	`FundsToDepositAccounts`	-	USD	2 Qtrs
Funds to deposit accounts, net	`FundsToDepositAccounts`	$4.48M	USD	2 Qtrs
Purchase of research and development licenses	`PaymentsToAcquireInProcessResearchAndDevelopment`	$594.00K	USD	2 Qtrs
Purchase of research and development licenses	`PaymentsToAcquireInProcessResearchAndDevelopment`	$1.11M	USD	2 Qtrs
Purchase of convertible note	`RepaymentOfConvertibleDebt`	-	USD	2 Qtrs
Purchase of convertible note	`RepaymentOfConvertibleDebt`	$2.00M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-26.48M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-70.41M	USD	2 Qtrs
Proceeds from issuance of common stock and warrants, net of offering cost	`ProceedsFromIssuanceCommonStockAndWarrantsNetOfOfferingCost`	$77.99M	USD	2 Qtrs
Proceeds from issuance of common stock and warrants, net of offering cost	`ProceedsFromIssuanceCommonStockAndWarrantsNetOfOfferingCost`	$6.56M	USD	2 Qtrs
Proceeds from issuance of common stock, net of offering cost	`ProceedsFromIssuanceOfCommonStock`	-	USD	2 Qtrs
Proceeds from issuance of common stock, net of offering cost	`ProceedsFromIssuanceOfCommonStock`	$17.84M	USD	2 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$7.20M	USD	2 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$84.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$31.61M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$78.07M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$2.74M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$5.00M	USD	2 Qtrs
Cash and cash equivalents, beginning of period	`CashEquivalentsAtCarryingValue`	$91.00K	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashEquivalentsAtCarryingValue`	$2.71M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashEquivalentsAtCarryingValue`	$7.72M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashEquivalentsAtCarryingValue`	$2.83M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashEquivalentsAtCarryingValue`	$91.00K	USD	Point-in-time
Cash and cash equivalents, end of period	`CashEquivalentsAtCarryingValue`	$2.71M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashEquivalentsAtCarryingValue`	$7.72M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashEquivalentsAtCarryingValue`	$2.83M	USD	Point-in-time

Stockholders Equity 26 line items

Line Item	Tag	Value	Unit	Period
Balance at	`StockholdersEquity`	$29.62M	USD	Point-in-time
Balance at	`StockholdersEquity`	$31.49M	USD	Point-in-time
Balance at	`StockholdersEquity`	$10.53M	USD	Point-in-time
Balance at	`StockholdersEquity`	$104.37M	USD	Point-in-time
Balance at	`StockholdersEquity`	$103.08M	USD	Point-in-time
Balance at	`StockholdersEquity`	$20.98M	USD	Point-in-time
Issuance of common stock and warrants (net of offering costs of $8,260)	`StockIssuedDuringPeriodValueOfCommonStockAndWarrants`	$77.99M	USD	2 Qtrs
Exercise of warrants	`StockIssuedDuringPeriodValueStockOptionsExercised`	$84.00K	USD	2 Qtrs
Issuance of common stock for research and development license acquired	`StockIssuedDuringPeriodValueIssuedForResearchAndDevelopmentLicenseAcquired`	$531.00K	USD	2 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition`	$175.00K	USD	2 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition`	$63.00K	USD	1 Quarter
Issuance of common stock, common warrants and prefunded warrants, net of offering cost	`StockIssuedDuringPeriodValueOther`	$6.56M	USD	2 Qtrs
Issuance of common stock, net of offering cost	`StockIssuedDuringPeriodValueNewIssues`	$17.84M	USD	2 Qtrs
Issuance of common stock, net of offering cost	`StockIssuedDuringPeriodValueNewIssues`	$12.77M	USD	1 Quarter
Common warrant and prefunded warrant exercise	`StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants`	$65.00K	USD	1 Quarter
Common warrant and prefunded warrant exercise	`StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants`	$7.20M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-5.31M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-2.31M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.35M	USD	1 Quarter
Net loss	`ProfitLoss`	$-10.65M	USD	2 Qtrs
Balance at June 30, 2021	`StockholdersEquity`	$29.62M	USD	Point-in-time
Balance at June 30, 2021	`StockholdersEquity`	$31.49M	USD	Point-in-time
Balance at June 30, 2021	`StockholdersEquity`	$10.53M	USD	Point-in-time
Balance at June 30, 2021	`StockholdersEquity`	$104.37M	USD	Point-in-time
Balance at June 30, 2021	`StockholdersEquity`	$103.08M	USD	Point-in-time
Balance at June 30, 2021	`StockholdersEquity`	$20.98M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.